Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Purchased by New York Life Investment Management LLC

New York Life Investment Management LLC lifted its holdings in Medpace Holdings, Inc. (NASDAQ:MEDPFree Report) by 104.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,477 shares of the company’s stock after buying an additional 1,266 shares during the period. New York Life Investment Management LLC’s holdings in Medpace were worth $600,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of MEDP. BlackRock Inc. raised its stake in Medpace by 0.9% during the first quarter. BlackRock Inc. now owns 3,792,694 shares of the company’s stock worth $620,448,000 after purchasing an additional 35,121 shares during the period. Wasatch Advisors Inc. raised its stake in Medpace by 12.1% during the first quarter. Wasatch Advisors Inc. now owns 2,728,392 shares of the company’s stock worth $446,338,000 after purchasing an additional 294,103 shares during the period. State Street Corp raised its stake in Medpace by 2.5% during the first quarter. State Street Corp now owns 899,855 shares of the company’s stock worth $147,207,000 after purchasing an additional 21,868 shares during the period. Dimensional Fund Advisors LP raised its stake in Medpace by 1.5% during the first quarter. Dimensional Fund Advisors LP now owns 656,864 shares of the company’s stock worth $107,456,000 after purchasing an additional 9,881 shares during the period. Finally, Geode Capital Management LLC raised its stake in Medpace by 0.4% during the first quarter. Geode Capital Management LLC now owns 587,944 shares of the company’s stock worth $110,563,000 after purchasing an additional 2,129 shares during the period. 77.98% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Robert W. Baird lifted their price target on shares of Medpace from $302.00 to $312.00 and gave the company an “outperform” rating in a research report on Wednesday, January 17th.

Get Our Latest Report on Medpace

Medpace Stock Up 3.1 %

NASDAQ MEDP opened at $318.43 on Friday. Medpace Holdings, Inc. has a 52 week low of $167.00 and a 52 week high of $318.96. The stock has a market capitalization of $9.77 billion, a PE ratio of 37.29 and a beta of 1.29. The firm has a 50 day moving average of $296.59 and a two-hundred day moving average of $272.22.

Insiders Place Their Bets

In other news, VP Susan E. Burwig sold 10,391 shares of the business’s stock in a transaction that occurred on Thursday, December 14th. The shares were sold at an average price of $304.15, for a total transaction of $3,160,422.65. Following the completion of the sale, the vice president now owns 17,292 shares in the company, valued at approximately $5,259,361.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, CEO August J. Troendle sold 7,871 shares of the company’s stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $272.18, for a total value of $2,142,328.78. Following the completion of the sale, the chief executive officer now owns 5,613,986 shares in the company, valued at approximately $1,528,014,709.48. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Susan E. Burwig sold 10,391 shares of the stock in a transaction on Thursday, December 14th. The stock was sold at an average price of $304.15, for a total transaction of $3,160,422.65. Following the sale, the vice president now owns 17,292 shares of the company’s stock, valued at approximately $5,259,361.80. The disclosure for this sale can be found here. Insiders sold 210,391 shares of company stock worth $58,708,131 in the last 90 days. Corporate insiders own 25.70% of the company’s stock.

Medpace Profile

(Free Report)

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.

Recommended Stories

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDPFree Report).

Institutional Ownership by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.